Falla cardíaca avanzada

Juan Manuel Senior, Nelson Darío Giraldo-Ramírez

Resumen


Introducción: la falla cardíaca avanzada es una enfermedad grave con síntomas persistentes y limitación funcional grave, a pesar del tratamiento médico óptimo.

Metodología: para la creación de la guía de práctica clínica (GPC) basada en la evidencia se siguieron los pasos definidos en la Guía Metodológica para la Elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano del Ministerio de Salud y Protección Social.

Resultados: se establecen las recomendaciones para el tratamiento de la falla cardíaca avanzada.

Conclusión: existen algunas alternativas terapéuticas como los dispositivos de asistencia ventricular y el trasplante cardíaco que impactan la mortalidad en este grupo de pacientes.


Palabras clave


Cuidados Paliativos; Guía; Insuficiencia Cardíaca

Texto completo:

PDF

Referencias


(1.) Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):684-94.

(2.) Barge-Caballeroa E, Paniagua-Martín MJ, Marzoa-Rivasa R, Campo-Pérez R, Rodrıíguez-Fernández JA, Pérez-Pérez A, et al. Utilidad de la escala INTERMACS para estratificar el pronóstico tras el trasplante cardiaco urgente. Rev Esp Cardiol. 2011 Mar;64(3):193-200. DOI 10.1016/j.recesp.2010.08.001.

(3.) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. DOI 10.1093/eurjhf/hfs105. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):361-2.

(4.) Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant. 2006 Sep;25(9):1024-42.

(5.) Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997 Jun;95(12):2660-7.

(6.) Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar;113(11):1424-33.

(7.) Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant. 2011 Nov;30(11):1236-43. DOI 10.1016/j.healun.2011.05.012.

(8.) Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, et al. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail. 2013 Sep;6(5):881-9. DOI 10.1161/CIRCHEARTFAILURE.112.000043.

(9.) Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, et al. Predictors of short term mortality in heart failure -insights from the Euro Heart Failure survey. Int J Cardiol. 2010 Jan;138(1):63-9. DOI 10.1016/j.ijcard.2008.08.004.

(10.) Scrutinio D, Ammirati E, Passantino A, Guida P, D’Angelo L, Oliva F, et al. Predicting short-term mortality in advanced decompensated heart failure - role of the updated acute decompensated heart failure/Nterminal pro-B-type natriuretic Peptide risk score. Circ J. 2015;79(5):1076-83. DOI 10.1253/circj.CJ-14-1219.

(11.) Kilic A, Allen JG, Weiss ES. Validation of the United States-derived Index for Mortality Prediction After Cardiac Transplantation (IMPACT) using international registry data. J Heart Lung Transplant. 2013 May;32(5):492-8. DOI 10.1016/j.healun.2013.02.001.

(12.) Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis. 2014 Aug;6(8):1120-8. DOI 10.3978/j.issn.2072-1439.2014.06.44.

(13.) Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991 Mar;83(3):778-86.

(14.) Cahalin LP, Chase P, Arena R, Myers J, Bensimhon D, Peberdy MA, et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev. 2013 Jan;18(1):79-94. DOI 10.1007/s10741-012-9332-0.

(15.) Cornelis J, Taeymans J, Hens W, Beckers P, Vrints C, Vissers D. Prognostic respiratory parameters in heart failure patients with and without exercise oscillatory ventilation – a systematic review and descriptive meta-analysis. Int J Cardiol. 2015 Mar;182:476-86. DOI 10.1016/j.ijcard.2015.01.029.

(16.) Poggio R, Arazi HC, Giorgi M, Miriuka SG. Prediction of severe cardiovascular events by VE/VCO2 slope versus peak VO2 in systolic heart failure: a metaanalysis of the published literature. Am Heart J. 2010 Dec;160(6):1004-14. DOI 10.1016/j.ahj.2010.08.037.

(17.) Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI,et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. J Heart Lung Transplant. 2012 Oct;31(10):1052-64. DOI 10.1016/j.healun.2012.08.002.

(18.) Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015 Mar;350:h870. DOI 10.1136/bmj.h870.

(19.) Li Y, Neilson MP, Whellan DJ, Schulman KA, Levy WC, Reed SD. Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. J Card Fail. 2013 May;19(5):311-6. DOI 10.1016/j.cardfail.2013.03.008.

(20.) Nagarajan V, Tang WH. Management of comorbid conditions in heart failure: a review. Med Clin North Am. 2012 Sep;96(5):975-85. DOI 10.1016/j.mcna.2012.07.006.

(21.) Bellotti P, Badano LP, Acquarone N, Griffo R, Lo Pinto G, Maggioni AP, et al. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all’Utilizzo delle Risore. Eur Heart J. 2001 Apr;22(7):596-604.

(22.) Stawicki S, Roik M, Jasik M, Kosior D, Scisło P, Kochanowski J, et al. Differences between cardiologists and internists in the management of heart failure. Medical guidelines compared with every-day practice. Kardiol Pol. 2004 Nov;61(11):431-9; discussion 440-1.

(23.) Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, et al. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013 Oct;51(10):901-7. DOI 10.1097/MLR.0b013e3182a3e525.

(24.) Steinman MA, Patil S, Kamat P, Peterson C, Knight SJ. A taxonomy of reasons for not prescribing guideline-recommended medications for patients with heart failure. Am J Geriatr Pharmacother. 2010 Dec;8(6):583-94. DOI 10.1016/S1543-5946(10)80007-8.

(25.) Feltner C, Jones CD, Cené CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014 Jun;160(11):774-84. DOI 10.7326/M14-0083.

(26.) Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart failure. Cochrane Database Syst Rev. 2012 Sep;(9):CD002752. DOI 10.1002/14651858.CD002752.pub3.

(27.) Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997 Sep;30(3):725-32.

(28.) Hershberger RE, Ni H, Nauman DJ, Burgess D, Toy W, Wise K, et al. Prospective evaluation of an outpatient heart failure management program. J Card Fail. 2001 Mar;7(1):64-74.

(29.) Whitty JA, Stewart S, Carrington MJ, Calderone A, Marwick T, Horowitz JD, et al. Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: findings from the Which? trial. PLoS One. 2013;8(3):e58347. DOI 10.1371/journal.pone.0058347.

(30.) Cline CM, Israelsson BY, Willenheimer RB, Broms K, Erhardt LR. Cost effective management programme for heart failure reduces hospitalisation. Heart. 1998 Nov;80(5):442-6.

(31.) Ledwidge M, Barry M, Cahill J, Ryan E, Maurer B, Ryder M, et al. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Eur J Heart Fail. 2003 Jun;5(3):381-9.

(32.) Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983 Oct;68(4):785-95.

(33.) The veterans administration coronary artery bypass surgery cooperative study group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med. 1984 Nov;311(21):1333-9.

(34.) VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation. 1992 Jul;86(1):121-30.

(35.) Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet. 1982 Nov;2(8309):1173-80

(36.) The principal investigators of CASS and their associates. The National Heart, Lung, and Blood Institute Coornary Artery Surgery Study CASS. Circulation. 1981Jun;63(Suppl 1):1-81.

(37.) Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med. 1985 Jun;312(26):1665-71.

(38.) O’Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol. 2002 Jul;90(2):101-7.

(39.) Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr;356(15):1503-16.

(40.) Kunadian V, Pugh A, Zaman AG, Qiu W. Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and metaanalysis of 19 clinical studies. Coron Artery Dis. 2012 Nov;23(7):469-79.

(41.) Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011 Feb;13(2):227-33. DOI 10.1093/eurjhf/hfq230.

(42.) Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011 Apr;364(17):1607-16. DOI 10.1056/NEJMoa1100356.

(43.) Carson P, Wertheimer J, Miller A, O’Connor CM, Pina IL, Selzman C, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-ofdeath results. JACC Heart Fail. 2013 Oct;1(5):400-8. DOI 10.1016/j.jchf.2013.04.012.

(44.) Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, et al. STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol. 2010 Aug;56(6):490-8. DOI 10.1016/j.jacc.2009.11.102.

(45.) Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR, et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol. 2014 Aug;64(6):553-61. DOI 10.1016/j.jacc.2014.04.064. Erratum in: J Am Coll Cardiol. 2014 Oct;64(14):1539.

(46.) Mark DB, Knight JD, Velazquez EJ, Wasilewski J, Howlett JG, Smith PK, et al. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. Ann Intern Med. 2014 Sep;161(6):392-9. DOI 10.7326/M13-1380.

(47.) Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982 Dec;66(6):1146-9.

(48.) Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007 Jul;32(7):375-410.

(49.) Takeishi Y, Tono-oka I, Kubota I, Ikeda K, Masakane I, Chiba J, et al. Functional recovery of hibernating myocardium after coronary bypass surgery: does it coincide with improvement in perfusion? Am Heart J. 1991 Sep;122(3 Pt 1):665-70.

(50.) Bax M, de Winter RJ, Schotborgh CE, Koch KT, Meuwissen M, Voskuil M, et al. Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction. J Am Coll Cardiol. 2004 Feb;43(4):534-41.

(51.) Adel W, Nammas W. Predictors of contractile recovery after revascularization in patients with anterior myocardial infarction who received thrombolysis. Int J Angiol. 2010 Summer;19(2):e78-82.

(52.) Shah BN, Khattar RS, Senior R. The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era. Eur Heart J. 2013 May;34(18):1323-36. DOI 10.1093/eurheartj/eht018.

(53.) Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008 Jan;117(1):103-14. DOI 10.1161/CIRCULATIONAHA.107.702993.

(54.) Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr;39(7):1151-8.

(55.) Beanlands R, Nichol G, Ruddy TD, deKemp RA, Hendry P, Humen D, et al. Evaluation of outcome and costeffectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Control Clin Trials. 2003 Dec;24(6):776-94.

(56.) Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007 Nov;50(20):2002-12.

(57.) D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009 Sep;2(9):1060-8. DOI 10.1016/j.jcmg.2009.02.017.

(58.) Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011 Apr;364(17):1617-25. DOI 10.1056/NEJMoa1100358.

(59.) Goel SS, Bajaj N, Aggarwal B, Gupta S, Poddar KL, Ige M, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014 Jan;63(2):185-6. DOI 10.1016/j.jacc.2013.08.723.

(60.) Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015 Mar;65(12):1231-48. DOI 10.1016/j.jacc.2015.02.009. Erratum in: J Am Coll Cardiol. 2015 May;65(20):2265.

(61.) Allen LA, Felker GM. Advances in the surgical treatment of heart failure. Curr Opin Cardiol. 2008 May;23(3):249-53. DOI 10.1097/HCO.0b013e3282f54fea.

(62.) Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003 Mar;91(5):538-43.

(63.) Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011 Apr;364(15):1395-406. DOI 10.1056/NEJMoa1009355. Erratum in: N Engl J Med. 2011 Jul;365(2):189.

(64.) Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol. 1996 Oct;78(8):966-9.

(65.) Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998 Feb;115(2):381-6; discussion 387-8.

(66.) Bishay ES, McCarthy PM, Cosgrove DM, Hoercher KJ, Smedira NG, Mukherjee D, et al. Mitral valve surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg. 2000 Mar;17(3):213-21.

(67.) Bolling SF. Mitral reconstruction in cardiomyopathy. J Heart Valve Dis. 2002 Jan;11 Suppl 1:S26-31.

(68.) Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005 Feb;45(3):381-7.

(69.) Shah AS, Hannish SA, Milano CA, Glower DD. Isolated mitral valve repair in patients with depressed left ventricular function. Ann Thorac Surg. 2005 Oct;80(4):1309-14; discussion 1314.

(70.) Barisani JL, Chada S, Christen A. Resultados del tratamiento quirúrgico de la insuficiencia mitral funcional en la miocardiopatía dilatada idiopática. Rev Argent Cir Cardiovasc. 2005;3(1):17-22.

(71.) The Heart Failure Network Research Group. Effectiveness of surgical mitral valve repair versus medical treatment for people with significant mitral regurgitation and non-ischemic congestive heart failure (SMMART-HF) [Internet]. [cited 2015 Mar 15mar]. Available from: http://www.mmrf.org/MMRF/library/research/files/archived/SMMART_Protocol_Feb_1_2008_Amendment_1_FINAL.pdf

(72.) Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. 2007 Jun;49(22):2191-201.

(73.) Gelsomino S, Lorusso R, Caciolli S, Capecchi I, Rostagno C, Chioccioli M, et al. Insights on left ventricular and valvular mechanisms of recurrent ischemic mitral regurgitation after restrictive annuloplasty and coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008 Aug;136(2):507-18. DOI 10.1016/j.jtcvs.2008.03.027.

(74.) Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012 May;125(21):2639-48. DOI 10.1161/CIRCULATIONAHA.111.072256.

(75.) Grossi EA, Woo YJ, Patel N, Goldberg JD, Schwartz CF, Subramanian VA, et al. Outcomes of coronary artery bypass grafting and reduction annuloplasty for functional ischemic mitral regurgitation: a prospective multicenter study (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Thorac Cardiovasc Surg. 2011 Jan;141(1):91-7. DOI 10.1016/j.jtcvs.2010.08.057.

(76.) Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation. 2012 Nov;126(21):2502-10. DOI 10.1161/CIRCULATIONAHA.112.143818.

(77.) Fattouch K, Guccione F, Sampognaro R, Panzarella G, Corrado E, Navarra E, et al. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg. 2009 Aug;138(2):278-85. DOI 10.1016/j.jtcvs.2008.11.010.

(78.) Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014 Dec;371(23):2178-88. DOI 10.1056/NEJMoa1410490.

(79.) Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014 Jul;148(1):e1-e132. DOI 10.1016/j.jtcvs.2014.05.014. Erratum in: J Thorac Cardiovasc Surg. 2014 Oct;64(16):1763.

(80.) National Clinical Guideline Centre (UK). Acute Heart Failure: Diagnosing and Managing Acute Heart Failure in Adults. London: National Institute for Health and Care Excellence (UK); 2014 Oct. [Internet]. [cited 2015 Nov]. Available from: https://www.nice.org.uk/guidance/cg187

(81.) Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.

(82.) Thorvaldsen T, Benson L, Hagerman I, Dahlström U, Edner M, Lund LH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Int J Cardiol. 2014 Jul;175(1):55-61. DOI 10.1016/j.ijcard.2014.04.243.

(83.) Dies F, Krell MJ, Whitlow P, Liang C, Goldenberg I, Applefeld MM, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation. 1986;74:11-38.

(84.) Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999 Aug;138(2 Pt 1):247-53.

(85.) Tsagalou EP, Anastasiou-Nana MI, Terrovitis JV, Nanas SN, Alexopoulos GP, Kanakakis J, et al. The longterm survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease. Int J Cardiol. 2006 Apr;108(2):244-50.

(86.) Drakos SG, Kanakakis JV, Nanas S, Bonios M, Kaldara E, Katsaros F, et al. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol. 2009 Feb;53(2):157-61. DOI 10.1097/FJC.0b013e31819846cd.

(87.) Nanas JN, Tsagalou EP, Kanakakis J, Nanas SN, Terrovitis JV, Moon T, et al. Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest. 2004 Apr;125(4):1198-204.

(88.) Tsagalou EP, Gounopoulos P, Terrovitis JV, Drakos SG, Katsaros FT, Kaldara EE, et al. Amiodarone attenuates the proarrhythmic effects of dobutamine in patients with advanced congestive heart failure. Hellenic J Cardiol. 2009 May-Jun;50(3):193-8.

(89.) Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J. 1998 Jan;135(1):121-9.

(90.) Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. valuation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46(3):191-6.

(91.) Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012 Mar;38(3):359-67. DOI 10.1007/s00134-011-2435-6.

(92.) Silvetti S, Greco T, Di Prima AL, Mucchetti M, de Lurdes CM, Pasin L, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomized trials. Clin Res Cardiol. 2014 Jul;103(7):505-13. DOI 10.1007/s00392-013-0649-z.

(93.) Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014 Aug;16(8):898-906. DOI 10.1002/ejhf.118.

(94.) Yi GY, Li JX, Zhang J, Niu LL, Zhang CY. Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis. Med Sci Monit. 2015 Mar;21:895-901. DOI 10.12659/MSM.893736.

(95.) James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation. 1995 Nov;92(9 Suppl):II191-5.

(96.) Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov;345(20):1435-43.

(97.) Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009 Dec;361(23):2241-51. DOI 10.1056/NEJMoa0909938.

(98.) Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007 Aug;50(8):741-7.

(99.) Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012 Jun;125(25):3191-200. DOI 10.1161/CIRCULATIONAHA.111.058412.

(100.) Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010 Apr;55(17):1826-34. DOI 10.1016/j.jacc.2009.12.052.

(101.) Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, et al. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. DOI 10.3310/hta17530.


Resumen : 557 PDF : 421

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2017 Iatreia

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

Esta publicación hace parte del Sistema de Revistas de la Universidad de Antioquia
¿Quieres aprender a usar el Open Journal system? Ingresa al Curso virtual
Este sistema es administrado por el Programa Integración de Tecnologías a la Docencia
Universidad de Antioquia
Powered by Public Knowledge Project